Investigational drug · Phase 3
DBV712
Also called: ViaskinTM Peanut
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Allergy, Peanut, Peanut Allergy.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
9
Any phase or sponsor naming "DBV712"
First trial start
2018
Dec 6, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DBV712", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergy, Peanut
- Peanut Allergy
Largest trials
Live from ClinicalTrials.gov: studies naming "DBV712" as an intervention, largest first.
- Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of AgePivotal-lookingActive, not recruiting
DBV TechnologiesIndustry
NCT05741476 · 600 participants (planned) · Start Feb 21, 2023 · Primary completion Nov 6, 2025
Drug: DBV712; DBV712 · For: Allergy, Peanut
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 87 sites in all
- Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut AllergyPivotal-lookingCompleted
DBV TechnologiesIndustry
NCT02636699 · 500 participants · Start Dec 2015 · Primary completion Aug 18, 2017
Drug: Viaskin Peanut 250mcg; Placebo · For: Peanut Allergy
Sites: Little Rock, Arkansas; San Diego, California; Stanford, California · 31 sites in all
- Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young ChildrenPivotal-lookingCompleted
DBV TechnologiesIndustry
NCT03859700 · 304 participants · Start Dec 6, 2018 · Primary completion May 13, 2025
Drug: DBV712 250 mcg · For: Peanut Allergy
Sites: Tucson, Arizona; Little Rock, Arkansas; Los Angeles, California · 26 sites in all
- Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in ChildrenPivotal-lookingActive, not recruiting
DBV TechnologiesIndustry
NCT03013517 · 300 participants · Start Jan 23, 2017 · Primary completion Nov 23, 2019
Drug: Viaskin Peanut 250µg · For: Peanut Allergy
Sites: Little Rock, Arkansas; San Diego, California; Stanford, California · 31 sites in all
- Safety of Epicutaneous Immunotherapy for the Treatment of Peanut AllergyPivotal-lookingCompleted
DBV TechnologiesIndustry
NCT01170286 · 100 participants · Start Jul 2010 · Primary completion Feb 2012
Drug: Whole peanut extract; Placebo formulation · For: Peanut Allergy
Sites: Little Rock, Arkansas; Denver, Colorado; Willingboro, New Jersey · 5 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01904604 · 75 participants · Start Sep 2013 · Primary completion Aug 2015
Drug: Placebo Viaskin® Patch; Low-dose DBV712 Viaskin® Patch and 1 more · For: Peanut Hypersensitivity; Food Hypersensitivity; Hypersensitivity and 1 more
Sites: Little Rock, Arkansas; Denver, Colorado; Baltimore, Maryland · 5 sites in all
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01197053 · 60 participants · Start Aug 2010 · Primary completion Feb 2015
Drug: Epicutaneous Immunotherapy; placebo of peanut · For: Peanut Allergy
Sites: Paris, France
DBV TechnologiesIndustry
NCT03352726 · 27 participants · Start Nov 24, 2017 · Primary completion Jun 29, 2018
Drug: DBV712 IHRP · For: Peanut Allergy
Sites: Little Rock, Arkansas; Aurora, Colorado
- Viaskin® Peanut (DBV712) Expanded Access ProtocolNo longer available
DBV TechnologiesIndustry
NCT04371627
Drug: Viaskin Peanut · For: Peanut Allergy
Newest research
PubMed records naming it or its code names, newest first.
- Deriving Health Utilities from the Food Allergy Quality of Life Questionnaire - Parent Form (FAQLQ-PF) Using Mapping and Discrete Choice Experiments.
Smith AB, Bromilow T, Mealing S, et al. · Patient Relat Outcome Meas 2025
- Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy.
Dupont C, Burks AW, Fleischer DM, et al. · Expert Rev Clin Immunol 2024
- Immune response evolution in peanut epicutaneous immunotherapy for peanut-allergic children.
Bastin M, Carr WW, Davis CM, et al. · Allergy 2023
- Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies.
DunnGalvin A, Fleischer DM, Campbell DE, et al. · J Allergy Clin Immunol Pract 2021
- Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results.
Fleischer DM, Shreffler WG, Campbell DE, et al. · J Allergy Clin Immunol 2020
- An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial.
Fleischer DM, Chinthrajah S, Scurlock AM, et al. · Allergy Asthma Proc 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.